BridgeBio's achondroplasia drug trial data published in NEJM

June 28, 2026 4:00 PM

BridgeBio Pharma (Nasdaq: BBIO) announced that results from its Phase 3 PROPEL 3 trial of oral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found